BIIB033

BIIB033 (also known as Anti-LINGO-1) is a monoclonal antibody targeting LINGO1. As of 2015 it was being developed by Biogen as a treatment for diseases such as multiple sclerosis and optic neuritis.<ref>

Biogen MS Drug Results Are 'Mildly Encouraging' In Eye Disease Test(link). Forbes.

</ref><ref>

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex(link). Clinical Trials.

</ref><ref>Tran, Jonathan Q.,

 Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033, 
 Neurology - Neuroimmunology Neuroinflammation, 
 
 Vol. 1(Issue: 2),
 pp. e18,
 DOI: 10.1212/NXI.0000000000000018,
 PMID: 25340070,
 PMC: 4202679,
 
 Full text,</ref>

See also

• Ocrelizumab

References

<references />